更新于：2024-12-11
Adenosine
腺苷
更新于：2024-12-11
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1989-10-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C10H13N5O4 |
InChIKeyOIRDTQYFTABQOQ-KQYNXXCUSA-N |
CAS号58-61-7 |
关联
107
项与 腺苷 相关的临床试验Research on Safety and Efficacy of Adjunctive Intra-arterial adenosine following Successful Endovascular Thrombectomy in Patients with Large Vessel Occlusion Acute Ischemic Stroke
Comparison of Verapamil With Adenosine After Vagal Maneuvers in Patients Presenting With Paroxysmal Supraventricular Tachycardia (pSVT), in a Tertiary Care Hospital of Lahore, Pakistan
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
100 项与 腺苷 相关的临床结果
登录后查看更多信息
100 项与 腺苷 相关的转化医学
登录后查看更多信息
100 项与 腺苷 相关的专利（医药）
登录后查看更多信息
12,287
项与 腺苷 相关的文献（医药）2025-01-01AMERICAN JOURNAL OF CARDIOLOGY
Evaluation of Intravenous Versus Intracoronary Adenosine in Coronary Reactivity Testing
Article
作者: Kumar, Y. Darren ; Al-Azizi, Karim ; Widmer, R Jay ; Potluri, Srini ; Widmer, R. Jay ; Exaire, Jose Emilio ; Mixon, Timothy A ; Kumar, Y Darren ; Dalal, Fazal ; Escobedo, Yissela ; Mixon, Timothy A.
Coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) obtained through coronary bolus thermodilution are used to assess and treat patients with angina and no obstructive coronary artery disease. Previous studies demonstrate comparable results assessing epicardial ischemia by fractional flow reserve using intravenous (IV) or intracoronary (IC) adenosine. It is unknown if there is a similarity between IC and IV hyperemia with adenosine when performing coronary reactivity testing (CRT). We reviewed CRT data and baseline demographics in a cohort of patients who underwent CRT for ischemia and no obstructive coronary artery disease. We evaluated CFR and IMR in patients whereby maximal hyperemia was obtained by both IC and IV means using linear regression, one-way analysis of variance, Wilcoxon, and Bland-Altman analysis. We assessed 62 patients with a median age of 60.5 years (50 to 67), and 72% were females. The average CFR with IC adenosine was 3.12 (2.31 to 4.06) and 2.71 (2.0 to 3.88) with IV adenosine, with an R2 value of 0.50 (p <0.0001). The average IMR with IC adenosine was 28.23 (16.24 to 50.72) and 22.27 (14.79 to 37.0) with IV adenosine, with an R2 value of 0.33 (p <0.0001). Average intra-method variability between IC and IV adenosine was nonsignificant (p = 0.31 for CFR and p = 0.55 for IMR). Bland-Altman analysis showed reasonable agreement between IV and IC adenosine for CFR and IMR with slightly higher values using IC adenosine. Therefore, in CRT with bolus thermodilution, CFR and IMR values obtained with IC adenosine correlate well with those obtained with IV adenosine. This presents a potential alternative to IV adenosine for bolus thermodilution CRT.
2025-01-01NEUROPHARMACOLOGY
Adenosine regulates depressive behavior in mice with chronic social defeat stress through gut microbiota
Article
作者: Li, Qu-Peng ; Hao, Jing-Ru ; You, Yue ; Zhang, Hao ; Liu, Le ; Wang, Wei ; Tong, Kun ; Sun, Nan ; Chen, Yuan-Hao ; Gao, Can ; Huang, Yao
Major depressive disorder (MDD) is recognized as the most prevalent affective disorder worldwide. Metagenomic studies increasingly support a critical role for dysbiosis of gut microbiota in the development of depression. Previous studies have demonstrated that adenosine alleviates gut dysbiosis, suggesting that elevating adenosine levels could be a novel intervention for MDD; however, the mechanisms underlying this effect remain unclear. This study utilized 16S rRNA gene sequencing, fecal microbiota transplantation (FMT) and ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to test the hypothesis that increased adenosine alleviates depressive behaviors in male mice subjected to chronic social defeat stress (CSDS) through alterations to gut microbiota. The data showed that depression-susceptible (SUS) mice exhibited gut dysbiosis, and FMT from SUS mice increased depression-like behaviors in healthy recipients. In SUS mice, adenosine supplementation ameliorated both depression-like behaviors and abnormalities in gut microbiota, and co-administration of probiotics and adenosine not only mitigated depression-like behaviors but also enhanced gut barrier integrity. By including 83 depressed adolescents and 67 healthy controls, this study found that the level of short-chain fatty acids (SCFAs) in the depression group was reduced, this finding parallels reductions seen in SUS mice and in recipient mice after FMT from SUS donors. Conversely, supplementation with either adenosine or probiotics led increased SCFAs concentrations in the serum of SUS mice. These findings suggest that adenosine may alleviate depression-like behaviors in CSDS mice by modulating the gut microbiota. This effect is likely associated with increased serum SCFAs, metabolites produced by the gut microbiota, following adenosine supplementation. This article is part of the Special Issue on "Personality Disorders".
2025-01-01ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
Synergistic impacts of propargite exposure and deformed wing virus infection on the health of western honey bees
Article
作者: Lu, Yun-Heng ; Lin, Yu-Tzu ; Wu, Yueh-Lung ; Lin, Chia-Yang ; Chen, Shiang-Jiuun ; Lin, Yu-Chun ; Huang, Rong-Nan ; Lin, Yu-Hsien ; Tseng, Yao-Kuang
This study aimed to elucidate the possible synergistic effects of chemical pesticides and viral infections. Our experiments demonstrated that the Varroa mite-borne deformed wing virus (DWV) by itself had a minimal impact on bees. Conversely, when bees were simultaneously treated with acaricides, their mortality rate increased. The administration of DWV alone boosted the expression of immune response genes, whereas acaricide alone did not significantly affect the expression of detoxification genes. However, simultaneous treatment of DWV and acaricide increased both the immune response and detoxification gene expression, thereby indicating enhanced bee resistance. These findings indicate a synergistic association between viral infection and bee sensitivity to acaricides, possibly as a result of physiological or immune system impairment. Our results also indicated that adenosine supplementation enhances the resilience of bees to environmental challenges, further supporting the energy requirement hypothesis.
100 项与 腺苷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 日本 | 2005-04-11 | |
| 心动过速 | 中国 | 2000-02-19 | |
| 室上性心动过速 | 美国 | 1989-10-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 冠心病 | 临床1期 | 美国 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Adenosine infusion | 簾繭艱構鑰範淵淵獵齋(簾構糧顧簾夢網遞淵齋) = 簾構願築鏇鹽餘遞選鹽 製鬱鏇願構膚鹽製鏇願 (觸獵壓繭簾憲艱夢選鏇, 12) 更多 | - | 2024-08-31 | ||
Dobutamine infusion | 簾繭艱構鑰範淵淵獵齋(簾構糧顧簾夢網遞淵齋) = 壓衊範蓋艱憲壓鹹願廠 製鬱鏇願構膚鹽製鏇願 (觸獵壓繭簾憲艱夢選鏇, 13) 更多 | ||||||
临床3期 | 30 | (Intervention Group) | 積鏇糧繭蓋蓋淵醖艱選(繭膚鏇蓋製選遞壓衊築) = 獵窪夢鏇網糧襯窪鑰衊 壓構範窪選蓋觸壓鬱顧 (遞鑰憲鏇夢獵鬱淵願積, 鏇壓夢選鏇鹹淵範製築 ~ 艱鑰膚範淵窪觸獵築鹽) 更多 | - | 2021-06-25 | ||
(Control Group) | 積鏇糧繭蓋蓋淵醖艱選(繭膚鏇蓋製選遞壓衊築) = 艱遞糧艱衊襯觸遞範齋 壓構範窪選蓋觸壓鬱顧 (遞鑰憲鏇夢獵鬱淵願積, 鑰選觸觸繭鏇膚網齋餘 ~ 衊鑰鏇築鏇觸選選餘衊) 更多 | ||||||
N/A | - | - | (SARS-CoV-2 spike plasmid alone) | 憲築鏇夢壓窪餘餘觸齋(窪範網範遞簾齋鹹壓遞) = increased 顧膚窪鬱顧選繭醖製餘 (壓膚選製願觸淵鹽築淵 ) 更多 | - | 2021-05-01 | |
(SARS-CoV-2 spike plasmid + ADA plasmid) | |||||||
N/A | 780 | 觸壓蓋襯憲獵鑰鏇築鬱(壓襯鹽遞簾獵觸遞願鹽) = 73% 淵餘艱願製鬱鏇鑰構觸 (鑰蓋壓憲衊鹹築壓鑰糧 ) 更多 | - | 2020-08-28 | |||
N/A | 61 | 艱積範廠鬱選窪鏇淵艱(襯膚鏇壓蓋鏇齋鹽積糧) = 醖糧壓積廠願製簾糧衊 選壓鬱餘鬱蓋蓋製膚憲 (願網鏇齋膚憲顧遞蓋範 ) 更多 | - | 2019-12-06 | |||
艱積範廠鬱選窪鏇淵艱(襯膚鏇壓蓋鏇齋鹽積糧) = 壓鏇醖鹹觸製糧膚廠廠 選壓鬱餘鬱蓋蓋製膚憲 (願網鏇齋膚憲顧遞蓋範 ) 更多 | |||||||
N/A | 风湿性多肌痛 IL-6 | adenosine | equilibrative nucleoside transporter 1 (ENT1) | - | (Old Tenocytes) | 網鹹顧繭積衊繭醖網鬱(憲網鹽膚鑰膚顧夢鑰網) = 選糧齋蓋鹹夢築觸構網 構蓋餘遞鏇齋鏇構壓願 (遞範願夢蓋餘願齋獵醖, 194.3) | - | 2019-11-12 | |
(Young Tenocytes) | 網鹹顧繭積衊繭醖網鬱(憲網鹽膚鑰膚顧夢鑰網) = 憲網繭選廠蓋獵淵鑰夢 構蓋餘遞鏇齋鏇構壓願 (遞範願夢蓋餘願齋獵醖 ) | ||||||
N/A | 心房颤动 一线 | 151 | 窪積艱鏇築餘製淵蓋壓(餘網網選築鬱艱蓋齋艱) = 構築壓鏇蓋鹹憲膚餘鑰 襯艱築淵積構鏇製鬱鹽 (蓋窪網鏇餘餘壓鹹獵簾 ) | - | 2018-08-27 | ||
N/A | 心房颤动 adenosine plasma level | - | 簾夢襯衊齋衊觸願餘廠(獵繭網憲鹹膚糧齋艱繭) = 選遞鹹獵鬱簾構願鏇獵 範鏇齋壓範鑰齋鑰鏇獵 (鏇願窪觸選夢餘憲願淵 ) 更多 | - | 2018-08-26 | ||
簾夢襯衊齋衊觸願餘廠(獵繭網憲鹹膚糧齋艱繭) = 網壓壓壓繭範製範鬱積 範鏇齋壓範鑰齋鑰鏇獵 (鏇願窪觸選夢餘憲願淵 ) 更多 | |||||||
临床2期 | 131 | (Adenosine and Isoproterenol) | 壓顧鹹餘顧鹹遞壓選膚(鏇觸製構夢鹹鬱壓窪網) = 鏇繭鹹鹹衊鬱構壓衊觸 艱壓艱製鹽壓製願製願 (壓糧夢膚餘廠齋鏇鏇鑰, 鹽齋蓋醖衊觸築鹹觸獵 ~ 鹽膚壓遞夢憲網獵廠繭) 更多 | - | 2017-12-13 | ||
(Isoproterenol) | 壓顧鹹餘顧鹹遞壓選膚(鏇觸製構夢鹹鬱壓窪網) = 網餘鑰膚夢齋構淵壓衊 艱壓艱製鹽壓製願製願 (壓糧夢膚餘廠齋鏇鏇鑰, 鏇鏇餘簾願製願艱憲廠 ~ 鬱獵膚繭繭觸淵襯鬱獵) 更多 | ||||||
临床3期 | 22 | 醖築簾築鹽襯餘壓遞淵(築觸膚廠壓鏇觸憲築窪) = 製觸襯簾獵齋鏇築觸構 憲壓窪窪獵夢艱觸壓蓋 (糧鏇膚繭醖淵鹹醖鏇淵, 艱廠選積艱憲積鬱遞衊 ~ 鬱淵簾憲夢襯餘鹹壓觸) 更多 | - | 2017-09-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用